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A hallmark of type 2 diabetes mellitus (T2DM) is the
development of pancreatic b cell failure, which
results in insulinopenia and hyperglycemia. We
show that the adipokine adipsin has a beneficial
role in maintaining b cell function. Animals geneti-
cally lacking adipsin have glucose intolerance due
to insulinopenia; isolated islets from these mice
have reduced glucose-stimulated insulin secretion.
Replenishment of adipsin to diabetic mice treated
hyperglycemia by boosting insulin secretion. We
identify C3a, a peptide generated by adipsin, as a
potent insulin secretagogue and show that the C3a
receptor is required for these beneficial effects of
adipsin. C3a acts on islets by augmenting ATP levels,
respiration, and cytosolic free Ca2+. Finally, we
demonstrate that T2DM patients with b cell failure
are deficient in adipsin. These findings indicate that
the adipsin/C3a pathway connects adipocyte func-
tion to b cell physiology, and manipulation of this
molecular switch may serve as a therapy in T2DM.
INTRODUCTION
The rising prevalence of obesity worldwide and its associated
metabolic derangements, such as T2DM, pose an enormous
public health challenge (Van Gaal et al., 2006). Diabetes is a
chronic and progressive disease characterized by insulin
resistance and insulinopenia resulting from b cell failure and
decreases in b cell mass (Ferrannini, 2010; Kasuga, 2006; Muoio
and Newgard, 2008). Despite initial success in glycemic control
with oral medications, patients with T2DM typically exhibit wors-
ening glucose homeostasis over the span of a few years (U.K.
Prospective Diabetes StudyGroup, 1995; Kahn et al., 2006;Mat-
thews et al., 1998; Turner et al., 1996). The natural history ofT2DM includes a continuous decline in b cell function as illus-
trated by longitudinal follow-up studies of patients (Festa et al.,
2006). This deterioration leads to the need for additional thera-
pies, as well as the cumulative development of diabetic
complications.
Obesity, adipose inflammation, and malfunction of b cells are
tightly associated with one another, but the molecular link re-
mains to be established (Lumeng and Saltiel, 2011). Increasing
adiposity is directly correlated with adipose inflammation and
elaboration of proinflammatory cytokines such as tumor necro-
sis factor-a, but whether this low-grade chronic inflammation is
sufficient to trigger islet dysfunction is unknown (Hotamisligil,
2006; Ouchi et al., 2011; Rosen and Spiegelman, 2006; Shoelson
et al., 2006). Other factors such as amyloidosis, glucolipotoxic-
ity, failure of b cell expansion, apoptosis, and b cell dedifferenti-
ation have also been posited (Kitamura, 2013; Leroith and Accili,
2008; Muoio and Newgard, 2008; Prentki and Nolan, 2006; Weir
et al., 2009).
Adipsin was the first adipokine described (Cook et al., 1987). In
fact, adipsin is one of the major proteins of adipose cells but
paradoxically declines in many animal models of obesity and
diabetes (Flier et al., 1987). Adipsin was later identified to be
complement factor D (Rosen et al., 1989; White et al., 1992),
which catalyzes the rate-limiting step of the alternative pathway
of complement activation (Xu et al., 2001). Since then, adipsin
has been shown to play pivotal roles inmodels of ischemia reper-
fusion (Stahl et al., 2003) and sepsis (Dahlke et al., 2011). Func-
tions of this molecule include both the formation of the C5–C9
membrane attack complex and the generation of a number of
signaling molecules, including the anaphylatoxins C3a and C5a
(Ricklin et al., 2010). However, the function of adipsin in relation
to energy homeostasis and systemic metabolism has been
unknown.
The increasing awareness of the interplay between the im-
mune system and adipose tissue biology focuses attention on
complement biology in the pathogenesis of T2DM (Shu et al.,
2012). Certain proteins of the complement pathway are preferen-
tially expressed in the adipose tissue, and some components,Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc. 41
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Figure 1. Adipsin Regulates Adipose Tissue
Inflammation and Protects against Diabetes
(A) WT and Adipsin/ mice were fed a HFD for
4 months, starting at 1 month of age, and visceral
adipose tissues were assayed for immune infiltra-
tion by qPCR.
(B and C) WT and Adipsin/ adipose tissues were
stained for crown-like structures (CLS). Repre-
sentative pictures are shown (B), and numbers of
CLS (C) were quantitated. Scale bar, 100 mm.
(D and E) WT and Adipsin/ adipose tissues were
stained with toluidine blue for mast cells. Repre-
sentative pictures are shown (D), and numbers of
mast cells (E) were quantitated. Scale bar, 25 mm.
(F) Glucose tolerance test (GTT) was performed on
WT and Adipsin/ mice fed a HFD for 16 weeks
with measurement of blood glucose concentra-
tions.
(G) Insulin tolerance test (ITT) was performed on
WT and Adipsin/ mice fed a HFD for 18 weeks
with measurement of blood glucose concentra-
tions. For GTT and ITT experiments, n = 12–16 per
genotype.
Error bars represent SEM. *p < 0.05 and **p < 0.01.
See also Figures S1 and S2.like adipsin, are dysregulated in models of obesity and diabetes
(Choy et al., 1992; Flier et al., 1987; Zhang et al., 2007). Recep-
tors for complement-derived peptides are widely expressed on
multiple immune cell types (Ricklin et al., 2010). Studies using
mice deficient in C3aR1 or employing an antagonist of the recep-
tor have shown protection against obesity, reductions in adipose
tissue inflammation, and improved insulin sensitivity (Lim et al.,
2013; Mamane et al., 2009).
We have now reassessed the role of adipsin in metabolic dis-
eases and diabetes by performing detailed metabolic analyses
of wild-type (WT) and Adipsin/ mice (Xu et al., 2001). Mice
lacking adipsin exhibit worsened glucose homeostasis when
placed under the metabolic stress of diet-induced obesity. This
is due primarily to an unexpected and striking requirement of
adipsin for proper insulin secretion by the pancreatic b cells.
C3a, downstream of adipsin catalytic action, robustly stimulates
insulin secretion when coupled to hyperglycemic signals. These
data establish adipsin as a major link among fat cells, obesity,
and b cell function.42 Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc.RESULTS
Ablation of Adipsin Leads to
Decreased Adipose Tissue
Inflammation but Exacerbation of
Diabetes
We analyzed Adipsin/ mice under
normal conditions and with exposure to
metabolic stress. On a regular diet, there
was no difference in weights between the
WT and adipsin-deficient groups (WT,
29.0 ± 0.3 g; Adipsin/, 28.9 ± 0.3 g) at
5 months of age. We also subjected WT
and Adipsin/ mice to a model of diet-
induced obesity using a high-fat, high-carbohydrate diet (HFD).
Levels of adipsin in the blood gradually decline with increased
exposure to HFD (Figures S1A and S1B available online).
Adipsin/ animals exhibited a mild but significant attenuation in
weight gain on a HFD for 12 weeks compared to WT (WT, 48.1 ±
1.1 g; Adipsin/, 46.4 ± 1.2 g; p < 0.01). As adipsin controls the
alternative complement pathway, we assessed adipose inflam-
mation in WT and Adipsin/ mice on a HFD. The degree of
adipose inflammation was dampened in the Adipsin/ mice
compared to that of WT, with decreased expression of macro-
phage genes (Cd11b, Cd11c, F4/80, and Mac2) and mast cell
genes (Mcpt4, Cma1, and Cpa3), but not the T cell coreceptors
(Cd4 and Cd8) (Figure 1A). Indeed, the numbers of macrophages
and crown-like structures were decreased in adipose tissues of
Adipsin/ mice as confirmed by histological analyses (Figures
1Band1C) (Lumengetal., 2007;Weisberget al., 2003).Mast cells,
which are putative pathogenic inflammatory cells, were similarly
diminished in adipose tissues of Adipsin/ mice, as confirmed
by toluidine blue staining (Figures 1D and 1E) (Shu et al., 2012).
AB
D
C
Figure 2. Adipsin Regulates Insulin
Secretion In Vivo and In Vitro
(A) WT andAdipsin/micewere fed a HFD diet for
4 months, starting at 1 month of age, and were
challenged with i.p. glucose injections. Plasma
insulin levels were assayed. n = 8–12 mice per
genotype.
(B and C) Pancreata fromWT and Adipsin/mice
fed a HFD diet for 4 months were collected, and
insulin immunohistochemistry staining was per-
formed. Representative pictures are shown (B),
and b cell area was quantitated (C). Scale bar,
400 mm.
(D) Glucose-stimulated insulin secretion assay on
islets fromWT and Adipsin/mice fed a HFD diet.
Error bars represent SEM. *p < 0.05 and **p < 0.01.
See also Figure S3.Obesity often positively correlates with glucose intolerance,
though there are notable exceptions, including the aP2-deficient
mice (Hotamisligil et al., 1996) and the adiponectin (Kim et al.,
2007) and mitoNEET (Kusminski et al., 2012) transgenic mice.
To interrogate the role of adipsin in glucose homeostasis, WT
and Adipsin/ mice were challenged with a glucose tolerance
test. Under the nondiabetogenic conditions of a chow diet,
Adipsin/ mice had similar glucose tolerance compared to
that of WT mice (Figure S2A). Exposure to a HFD for 8 weeks re-
vealed similar glucose tolerance between WT and Adipsin/
mice (Figure S2B). However, after a longer exposure of 16 weeks
to a HFD, Adipsin/ mice displayed significantly impaired
glucose tolerance despite being leaner thanWTmice (Figure 1F).
To assess whether these changes were due to insulin resistance,
we performed an insulin tolerance test on obese WT and
Adipsin/ mice on a HFD for 18 weeks. Unexpectedly, WT
and Adipsin/ mice had a similar response to exogenous
insulin, indicating no gross changes in insulin sensitivityCell 158,(Figure 1G). Mild changes in insulin sensi-
tivity cannot be ruled out. Based on these
data, we considered the possibility that
Adipsin/ mice may be deficient in
insulin.
Loss of Adipsin Results in
Insulinopenia
To assess the possibility that adipsin
regulates insulin secretion, we assayed
insulin levels in WT and Adipsin/ mice
on a HFD. Adipsin/ mice on a shorter
term HFD had comparable insulin levels
in response to a glucose challenge
(Figure S3A); this is consistent with the
similar glucose tolerance observed be-
tween WT and Adipsin/ mice with the
shorter exposure to HFD. In contrast,
Adipsin/ mice on long-term HFD had
lower fasting insulin levels (Figure 2A).
Importantly, insulin levels remained low
upon glucose challenge, thus confirmingthat Adipsin/ mice are insulinopenic (Figures 2A and S3B).
These findings implicated b cell insufficiency as an obvious
explanation for the hyperglycemia in Adipsin/ mice. This
may, in theory, result from either decreased b cell mass or func-
tion. To assess for a quantitative defect in b cells, we performed
insulin immunohistochemistry on WT and Adipsin/ pancreata
and found no significant differences in islet morphology or b
cell area (Figures 2B and 2C). To directly interrogate whether
loss of adipsin impaired b cell function, we isolated islets from
WT and Adipsin/ mice that had been on a HFD. Islets from
Adipsin/mice on a HFD exhibited diminished insulin secretion
in response to glucose, recapitulating the in vivo phenotype (Fig-
ure 2D). The accumulation of islet-associated macrophages is
sometimes correlated with deterioration in b cell function (Ehses
et al., 2007; Homo-Delarche et al., 2006). In contrast to the
decreased number of adipose tissue macrophages in
Adipsin/mice, there was no change in islet-associatedmacro-
phages between WT and Adipsin/mice (Figure S3C). The loss41–53, July 3, 2014 ª2014 Elsevier Inc. 43
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Figure 3. Restoration of Adipsin Improves
Insulin Secretion and Glucose Homeostasis
(A) Diabetic db/db mice (3 months old) were
treated i.v. with 2 3 109 IFU of control lacZ or
adipsin adenovirus vectors, and 5 days later serum
adipsin was assessed by western blot.
(B and C) Control lacZ- and adipsin-transduced
mice were challenged by an i.p. GTT with mea-
surements of blood glucose (B) and plasma insulin
(C). n = 6 mice per group.
(D) Gluconeogenesis was determined by hepatic
Pepck and G6pc gene expression.
Error bars represent SEM. *p < 0.05, **p < 0.01,
and ***p < 0.001. See also Figure S4.of adipsin did not affect b cell insulin secretion in response to
glucose in islets frommice on a regular diet, indicating that there
is not a gross developmental defect in islets from adipsin null
mice (Figure S3D). These results suggest a role for adipsin in sus-
taining insulin production and/or secretion in diabetes.
Systemic Restoration of Adipsin Augments Insulin
Secretion and Improves Glucose Homeostasis
To determine whether adipsin can be therapeutically relevant for
the treatment of diabetes, we acutely restored adipsin expres-
sion in diabetic mice and asked whether augmenting adipsin
levels can improve diabetes. We have previously shown that
adipsin is dramatically reduced in genetic models of obesity
such as db/db mice (Flier et al., 1987). Importantly, these mice
have no genetic defect in the Adipsin gene but demonstrate a
potentially pathogenic loss of protein expression. Diabetic db/
db mice were injected with adenoviral vectors expressing either
control lacZ or adipsin. As expected, these vectors are taken up
by the liver and cause liver secretion of adipsin into the systemic
circulation. db/dbmice injected with adipsin adenovirus robustly
restored circulating adipsin levels to that above WT. In contrast,
mice that received the control lacZ virus remained deficient in
adipsin (Figure 3A). To determine whether replenishment of
adipsin in diabetic mice ameliorates hyperglycemia, glucose
tolerance tests were performed. Diabetic mice that had received
the adipsin adenovirus showed a significant decrease in fasting
glucose levels (lacZ 182 ± 13 mg/dl; adipsin 144 ± 7 mg/dl;
p < 0.05) and a dramatic enhancement in glucose clearance (Fig-
ure 3B). To assesswhether the improvements in glucose homeo-
stasis from adipsin therapy were linked to insulin secretion, we
assayed insulin levels. Indeed, both fasting insulin and
glucose-induced insulin levels were substantially increased in44 Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc.the adipsin-treated db/db mice (Fig-
ure 3C). As insulin can suppress gluco-
neogenesis through both direct and
indirect effects on the liver, we tested
whether adipsin treatment resulted in
decreased gluconeogenic gene expres-
sion. As expected based on insulin levels,
mice treatedwith adipsin had significantly
decreased expression of Pepck and
G6pc compared to those treated with
control (Figure 3D). The expression ofCrp was reduced, but many markers of inflammation such as
Il1b, Il6, and Tnf were unchanged between control and adip-
sin-treated groups (Figures S4A–S4E). It is possible that adipsin
or its products may have additional direct effects on the liver.
There was no significant change in weight loss as a result of
adenoviral infection and the fasting between the control and
lacZ groups (Figure S4F). Together, our data clearly show that
adipsin-directed therapy augments insulin secretion and has
antidiabetic actions.
C3a Stimulates Islet Insulin Secretion and Cytosolic
Free Ca2+ in Response to Glucose and KCl
To assess how adipsin modulates b cell function, we examined
whether adipsin and other complement factors are made locally
by the islets. We found that adipsin is predominantly made by
adipose tissue and not by the islets (Figure 4A). Similarly, other
key components of the proximal portion of the alternative
pathway, C3 and complement factor B, are both circulating
factors and produced outside of the islets (Figures 4B and
S5A–S5C). In order for adipsin to have distal/endocrine-like
effects on the islets of Langerhans, it is possible that it liberates
a peptide such as C3a or C5a that can act on b cells via the com-
plement receptors. To test this idea, we first analyzed islets for
expression of the C3a and C5a receptors by flow cytometry.
C3aR1 was expressed in the islets, but C5aR1 and C5L2 were
not readily detected (Figures 4C–4E). These data suggest that
C3aR1 is expressed on b cells, raising the possibility that C3a
may act on b cells to influence insulin secretion. C3a is detect-
able in the serum at a concentration of 25–50 ng/ml, though
this band likely reflects both C3a and its inactivated form, C3a-
desArg (Figure S5D). To determinewhether C3a can induce insu-
lin secretion, islets were subjected to a glucose stimulated
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Figure 4. C3a Stimulates Pancreatic b Cells to Secrete Insulin
(A and B) Relative expression of Adipsin (A) and C3 (B) in liver, quadriceps muscle (quad), islets, epididymal (epi), and inguinal (ing) fat were quantitated by qPCR.
(C–E) Flow cytometry was performed on islet cells with antibodies to receptors C3aR1 (C), C5aR1 (D), and C5L2 (E).
(F and G) Islets fromWTmice on a chow diet (F) or HFD (G) were subjected to a GSIS assay with recombinant C3a or C5a (100 nM) at the indicated concentrations
of glucose.
(H and I) db/dbmice (3 months old) transduced with lacZ or adipsin adenovirus were treated with vehicle or C3aR antagonist (SB 290157) and subjected to GTT
with measurements of blood glucose (H) and plasma insulin (I). Data were pooled from two experiments. Statistics for GTT assays between groups: lacZ/vehicle
versus adipsin/vehicle, p = 0.05; adipsin/vehicle versus adipsin/SB 290157, p < 0.01; lacZ/SB 290157 versus adipsin/vehicle, p < 0.01. n = 12–15mice per group.
Error bars represent SEM. *p < 0.05. See also Figure S5.insulin secretion (GSIS) assay in the presence of C3a. Acute
administration of C3a (the direct product of C3 convertase
generated by adipsin) enhanced insulin secretion by 30%–40%
in the presence of high, but not low, glucose conditions (Fig-
ure 4F). C5a did not show this effect (Figure 4F). Adipsin andC3 (the precursor to C3a) failed to enhance GSIS, further con-
firming the specificity of C3a (Figure S5E). Over time, islets
from patients with T2DM develop b cell failure, manifested by a
diminished insulin secretory response to glucose (Ashcroft and
Rorsman, 2012). We thus interrogated the ability of C3a toCell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc. 45
rescue b cell function in islets isolated from diabetic mice fed a
HFD. C3a stimulated insulin secretion in diabetic islets, suggest-
ing that C3a is an insulin secretagogue, with potential relevance
in diabetes (Figure 4G). Islets isolated from Adipsin/mice fed a
HFD are not further stimulated by C3a (Figure S5F). This sug-
gests that these islets may be impaired from chronic lack of
C3a and/or exposure to exacerbated glucolipotoxicity in
Adipsin/mice. In addition, adipsin or other products of adipsin
action may be important in sustaining islet health.
To dissect the requirement for the C3a/C3aR1 pathway in the
anti-diabetic actions of adipsin in vivo, we blocked C3aR1 func-
tion in db/db mice transduced with adipsin adenovirus. Mice
were treated with vehicle or the C3aR1 antagonist, SB 290157
(Ames et al., 2001; Lim et al., 2013), after injection of adeno-
virus. The group injected with the adipsin adenovirus and also
treated with the C3aR1 antagonist nearly completely reversed
the improvements in glucose tolerance and insulin secretion
conferred by the adipsin adenovirus alone (Figures 4H and 4I).
Insulin was induced 2.1-fold in the adipsin versus vehicle group,
and this was reduced by the C3aR antagonist to 1.4-fold, which
was similar to the control groups (Figure S5G). Taken together,
our data indicate that adipsin stimulates insulin secretion via
actions of C3a on its receptor to improve glucose homeostasis
in vivo.
To dissect the mechanism of C3a action on pancreatic islets,
we assessed whether C3a acts in the presence of KCl or the
sulfonylurea tolbutamide, which is an inhibitor of the ATP-
dependent K+ channel. C3a further stimulated insulin secretion
in conjunction with both KCl (Figure 5A) and tolbutamide (Fig-
ure 5B), suggesting either synergy or that its actions are down-
stream of the ATP-dependent potassium channel. Additionally,
these data suggest that targeting the adipsin/C3a pathway can
be used in combination with existing therapies for T2DM. b cell
calcium (Ca2+) handling is a major regulator of insulin secretion
(Rorsman et al., 2012; Tarasov et al., 2012; Yang and Berggren,
2006). To determine whether C3a augments the concentration of
cytosolic free Ca2+ [Ca2+]i as a mechanism to increase insulin
secretion, we assessed [Ca2+]i in islets stimulated with C3a in
response to glucose and KCl. Islets were perifused with different
concentrations of glucose and KCl in the presence or absence
C3a and then imaged to determine [Ca2+]i. The basal levels of
[Ca2+]i at 3 mM glucose were similar in control and C3a-treated
islets (Figure 5C). In contrast, C3a potently augmented [Ca2+]i in
islets in response to both glucose and KCl (Figure 5C). The
response times were similar in C3a-treated and control islets.
C3a robustly increased the peak [Ca2+]i and area under the curve
by 50% for glucose and nearly 100% for KCl (Figures 5D and
5E). Collectively, these results indicate that C3a enhances insulin
secretion in response to multiple secretagogues at least in part
by increasing [Ca2+]i flux.
Glucose entry into b cells stimulates mitochondrial oxygen
consumption to increase production of ATP, thereby triggering
insulin release and the metabolic amplifying pathway (Maechler,
2013; Prentki et al., 2013). We assessed whether C3a can
augment intracellular ATP levels and increase mitochondrial
oxygen consumption as a mechanism to stimulate insulin
release. Treatment of islets with C3a increased intracellular
ATP levels at high (20 mM), but not low (3 mM), glucose concen-46 Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc.trations (Figure 5F). Furthermore, islets treated with C3a dis-
played increased oxygen consumption with glucose challenge
compared to control islets (Figure 5G). The C3a-mediated
increase in oxygen consumption was largely driven by ATP-
coupled respiration (Figure 5H). These data suggest that C3a in-
creases intracellular ATP levels and stimulates ATP-coupled
respiration as a mechanism to enhance insulin secretion.
T2DM Patients with b Cell Failure Display Reduced
Levels of Adipsin
Human patients with T2DM develop evidence of b cell dysfunc-
tion (Ferrannini, 2010; Prentki and Nolan, 2006). A subset of
T2DM patients will develop significant b cell failure and require
treatment with exogenous insulin. Given our data in mice that
correlate adipsin expression with insulin secretion, we hypothe-
sized that adipsin might be dysregulated in diabetic patients with
b cell insufficiency. Adipsin expression was therefore measured
in the adipose tissues of diabetic patients with or without evi-
dence of b cell failure. Patients were segregated into two groups:
T2DM or T2DM with b cell failure (T2DM-bCF) according to
treatment with insulin. Patients undergoing elective abdominal
surgery were matched for age, gender, body mass index (BMI),
and fat mass (Table S1) (Klo¨ting et al., 2010). Importantly, the
mean fasting blood glucose and hemoglobin A1c were not
different between the two groups, indicating similar glycemic
control (Table S1). Adipsin mRNA was significantly decreased
in both visceral and subcutaneous adipose tissues of T2DM-bCF
compared to T2DM patients (Figure 6A). Adipokine expression
generally correlates with the degree of adiposity (Deng and
Scherer, 2010). We therefore tested other adipokines to rule
out a general dysregulation of adipokines in patients with b cell
failure, thereby assessing the specificity of the decrease in Adip-
sin. Leptin and adiponectin are extensively studied adipokines
that have previously been linked to b cell function (Dunmore
and Brown, 2013). We found that Leptin and Adiponectin
mRNA levels were not altered between T2DM and T2DM-bCF
patients (Figures 6B and 6C). These results demonstrate the
specificity of the decrease in Adipsin in diabetic patients with b
cell failure and argue against widespread alterations in adipokine
gene expression.
Moderate reductions in adipose production of adipsin may
potentially be compensated by proportional increases in
adipose tissue mass. Because adipsin is a secreted factor
derived from adipose tissues, we asked whether the reductions
in Adipsin mRNA seen in T2DM-bCF patients translated to
lower circulating adipsin. To this end, we tested serum adipsin
levels in patients with T2DM and T2DM-bCF. Circulating adip-
sin levels were significantly decreased in T2DM-bCF compared
to T2DM patients (Figure 6D). The decline in adipsin was not a
consequence of an overall reduction in adipokines as circu-
lating leptin and adiponectin were unaltered between T2DM
and T2DM-bCF patients (Figures 6E and 6F). Earlier studies
had shown that human subjects with mild to moderate obesity
did not have reduced levels of circulating adipsin (Napolitano
et al., 1994; Pomeroy et al., 1997). Although there is a reduction
in adipsin production per unit of adipose tissue, the expansion
of fat mass in obesity may compensate to keep circulating
adipsin levels high. Taken together, this suggests that adipose
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Figure 5. C3a Stimulates Cytoplasmic Free Ca2+ ([Ca2+]i) and Oxygen Consumption in Islets
(A and B) Islets were treated with C3a (100 nM) in conjunction with 30 mM KCl (A) or 0.25 mM tolbutamide (B) and assayed for insulin secretion.
(C–E) [Ca2+]i was measured in islets treated with control or C3a and stimulated with 20 mM glucose, washed with 3 mM glucose, stimulated with KCl, and then
washed with 3 mM glucose. The peak [Ca2+]i (D) and [Ca
2+]i area under the curve (E) are quantified.
(F) Intracellular ATP levels were determined after treatment of islets with C3a at 3 or 20 mM glucose. Data were pooled from three experiments.
(G and H) Oxygen consumption rates (OCR) were measured in islets treated with C3a and the following treatments: 20 mM glucose, oligomycin, rotenone, and
antimycin A. Statistical analysis was performed on traces prior to oligomycin. Data were pooled from three experiments.
(H) ATP-coupled respiration of islets is quantified.
Error bars represent SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 6. Adipsin Is Decreased in Patients with Type II Diabetes Mellitus with b Cell Failure
(A–F) T2DM patients were classified according to those on oral metformin therapy (type II diabetes mellitus, T2DM) or T2DM patients with b cell failure
(T2DM-bCF) for those on insulin therapy.
(A–C) Visceral and subcutaneous (SubQ) adipose tissue samples from T2DM and T2DM-bCF patients were analyzed for Adipsin (A), Adiponectin (B), and Leptin
(C) mRNA levels.
(D–F) Circulating adipsin (D), adiponectin (E), and leptin (F) levels were measured from blood samples of T2DM and T2DM-bCF patients. Adiponectin and leptin
are plotted according to male and female.
Error bars represent SEM. *p < 0.05. See also Table S1.
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production of adipsin and systemic levels of adipsin may
initially be higher in metabolic syndrome and early stages
of diabetes as a compensatory mechanism but then decline
with adipose dysfunction. These T2DM patients may then
develop b cell failure. Our data provide evidence for adipsin
as a key molecular link to the development of b cell failure
in T2DM.
DISCUSSION
Obesity has long been correlated with insulin resistance. In
addition, obesity, at least in its early stages, often provokes
compensatory hyperinsulinemia. These clinical observations
have raised the possibility that adipose cells themselves might
send important signals concerning their status to the pancreatic
islets. There have been conflicting reports on whether the adipo-
kine adiponectin can directly boost insulin secretion (Okamoto
et al., 2008; Staiger et al., 2005; Winzell et al., 2004). Recently,
a small-molecule adiponectin receptor agonist has been
reported and found to improve insulin sensitivity but had no ef-
fects on insulin secretion (Okada-Iwabu et al., 2013). The present
study identifies adipsin, one of the most abundant and specif-
ically expressed adipose proteins, as a circulating factor linking
fat cells and obesity to b cell function. Just as incretins provide
cues from the gastrointestinal system, adipsin appears to impart
signals along the adipose to pancreatic islet axis. In addition,
we find that adipsin is selectively decreased in T2DM patients
with b cell failure. It will be important to determine the factors
that suppress Adipsin expression in vivo in rodents and humans.
Our prior work suggests that there are transcription factors or
cofactors that bind to the Adipsin gene specifically in obesity
(Platt et al., 1994). Understanding the factors that inhibit Adipsin
expression can help us to develop strategies to reverse this
repression.
Replenishment of adipsin for a few days to diabetic db/
db mice with moderately severe diabetes was able to have
significant antidiabetic effects. And as adipsin is an abundant
circulating factor normally found in the bloodstream, this sug-
gests that adipsin may be an excellent therapy for diabetes
with a wide therapeutic window. As is the case with many
new potential therapies, validation of adipsin in additional ani-
mal models of diabetes with b cell failure will be needed prior
to potential clinical testing. The data here suggest that adipsin
acts, at least in part, via C3a to potentiate insulin secretion.
Adipsin/factor D cleaves factor B only when in complex with
C3b, catalyzing the formation of the C3 convertase (C3bBb),
which can act on C3 to liberate C3a. C3a potentiates insulin
secretion only when glucose levels are elevated. At low glucose
conditions, C3a does not induce b cells to release insulin. This
makes C3a an ideal drug that has a built-in negative feedback
system protecting against hypoglycemia. Furthermore, C3a is
rapidly inactivated by serum carboxypeptidases to the inert
C3a-desArg. Thus, it is highly likely that, although adipsin is
secreted mainly or exclusively by fat and reaches islets via the
circulation, it meets the C3bB proconvertase complex in the
vicinity of the b cells. The islets may be a privileged docking
site of the proconvertase to allow adipsin to amplify generation
of C3a locally before its conversion to the inert C3a-desArg.Future research focusing on the regulation of C3a production
at the level of the islets is needed. It is also possible that
C3aR1 may have other diabetes-modifying functions in other
metabolic tissues because it is fairly widely expressed. Addi-
tionally, strategies aimed at antagonizing the carboxypepti-
dase(s), responsible for inactivation of C3a specifically near
the islets, draw a potential parallel with incretins and inhibition
of dipeptidyl peptidase-4. This approach may potentially
be limited by the anaphylatoxin activity of C3a, translating to a
narrower therapeutic window.
C3aR1 is a G-protein-coupled receptor that is pertussis toxin
sensitive; in other systems, it has been shown to enhance [Ca2+]i
flux and activate MAPK/ERK, Rho, and NF-kB signaling path-
ways. C3a may work by a number of these different mechanisms
on pancreatic islets. Isolated islets perifused with glucose or KCl
in the presence of C3a show 50%–100% increases in [Ca2+]i.
These effects may be from modulation of the SERCA pump to
affect Ca2+ stores that, when released, would increase peak
[Ca2+]i. In addition, C3a drives islet mitochondrial respiration,
potentially as a result of increases in ATP and/or in intramito-
chondrial Ca2+ and their effects on many enzymes of the Krebs
cycle (Tarasov et al., 2012). There may be other C3a signaling
pathways that do not directly affect Ca2+ feeding into the meta-
bolic-amplifying pathway of nutrient-induced insulin secretion
(Henquin, 2011). C3aR1 is expressed in a number of metabolic
tissues and may have other functions aside from its effects on
the pancreatic islets.
It is widely accepted that full-length C3a is the active molecule
on C3aR1, whereas C3a-desArg is the inactive form. There have
been some data suggesting that C3a-desArg stimulates lipogen-
esis, but these have been disputed (Baldo et al., 1993; Wetsel
et al., 1999). Importantly, our study used active C3a at relatively
low doses, which is consistent with a bona fide C3a-based
mechanism. However, it is unclear whether the less active
C3a-desArg could affect the b cell functions shown here when
present at supraphysiologic doses (Ahren et al., 2003). Future
studies dissecting the mechanisms of C3a/C3aR1 signaling on
b cells will help to determine the conserved and specialized
signaling pathways utilized by b cells.
Here, we show that the actions of adipsin in the augmen-
tation of insulin secretion are at least partly through C3aR1.
The Adipsin/ and C3aR1/ mice show some similarities on
a HFD. Both mice are leaner and have decreased adipose tissue
inflammation compared to WT (Mamane et al., 2009). At first
glance, there seem to be discrepancies with the adipsin null
mice showing exacerbated glucose intolerance and the
C3aR1/ mice with improved glucose tolerance. In Mamane
et al. (2009), glucose tolerance of the C3aR1/mice was exam-
ined at 8 weeks on a HFD. Similarly, at 8 weeks of HFD, we
observed a small nonsignificant trend toward improved glucose
tolerance in the Adipsin/ mice (Figure S2B). It is only after a
longer exposure to HFD, which presumably allows b cell failure
to develop, that the insulinopenia phenotype is unmasked. Abla-
tion of adipsin would disrupt generation of the C3 convertase but
still permits low levels of C3a generated from spontaneous hy-
drolysis of C3, the so-called ‘‘C3 tickover.’’ Another possibility
is that adipsin may have other effects that do not depend on
C3aR1.Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc. 49
The present study is the first report of altered adipsin levels in
a subset of patients with T2DM. Measurement of adipsin levels
may also prove to be valuable from a diagnostic standpoint to
identify those patients at high risk of developing b cell failure
and accelerated diabetes. T2DM patients may be risk stratified
based on their adipsin level, and those with the lowest levels
may warrant closer follow up even when other glycemic indices
such as the hemoglobin A1c are well controlled. This group may
benefit from earlier introduction of insulin therapies. Alterna-
tively, theremay be a group of patients with high levels of adipsin
who may be protected from T2DM such as the ‘‘metabolically
healthy but obese’’ (Klo¨ting et al., 2010; Primeau et al., 2011).
We chose insulin therapy as a surrogate for b cell insufficiency,
but not all patients being treated with insulin may have bona
fide b cell failure. Thus the level of adipsin in T2DM patients
with b cell failure may be even lower. It is also possible that exog-
enous insulin therapy may repress Adipsin, but not the other
adipokines (Adiponectin and Leptin) tested in our study. Future
prospective studies using adipsin to predict the development
of T2DM in nondiabetic patients or progression of diabetes in
T2DM patients are needed to answer these questions. Thus,
we shed light on a previously unrecognized adipose to pancreas
pathway with potential diagnostic and therapeutic utility in meta-
bolic diseases.
EXPERIMENTAL PROCEDURES
Mice and Treatments
WT and Adipsin/ mice were backcrossed 7–10 generations to C57BL/6
background. Controls from the same backcrossed generations were used
for experiments. Mice were fed a regular chow diet or a 60% kCal HFD
(Research Diets). db/db mice were purchased from Jackson laboratories.
For adenoviral expression studies, mice were injected intravenously (i.v.)
with lacZ or adipsin-expressing adenoviral vectors (Life Technologies) and as-
sayed 5 days later. For C3aR1 antagonist experiments, SB 290157 (Millipore)
dosed at 30 mg/kg or vehicle (10% ethanol) was administered by intraperito-
neal (i.p.) injections bis in die (twice a day, b.i.d.) from days 3–5 after adeno-
virus. Mice were fasted overnight for glucose tolerance tests and given an
i.p. injection of D-glucose (1 g/kg body weight for HFD and db/db mice;
2 g/kg for regular diet mice and for insulin induction). For insulin tolerance
tests, mice were fasted for 5 hr and given an i.p. injection of insulin (0.75
units/kg body weight). Blood samples were taken from the tail vein and
measured with a glucometer. The mice were housed in a facility accredited
by the American Association for Laboratory Animal Care. The Institutional
Animal Care and Use Committee of the Beth Israel Deaconess Medical Center
approved studies using animals.
Antibodies and Reagents
Recombinant C3a and C5a proteins (R&D) were used at a concentration of
100 nM. Adipsin (R&D) and C3 (Calbiochem) proteins were used at 1 mg/ml.
Anti-adipsin antibody (Santa Cruz) was used for western blot analysis.
Antibodies to C3aR1 (Santa Cruz), C5aR1 (Biolegend), and C5L2 (Hycult)
were used for flow cytometry. RNA isolation and reverse transcription were
performed with Trizol (Life Technologies), RNeasy (QIAGEN), and cDNA syn-
thesis (Agilent) kits. qPCR reactions were done with SYBR green on an ABI
7900HT (Life Technologies).
Islet Studies
Islets were isolated from pancreata with collagenase digestion as previously
described (Danial et al., 2008). For static incubation (batch release) assays,
we handpicked islets and placed them into basal Krebs buffer containing
3mM glucose followed by transfer into Krebs solution containing the indicated
concentrations of glucose or secretagogues. After 45 min incubation at 37C,50 Cell 158, 41–53, July 3, 2014 ª2014 Elsevier Inc.islets were pelleted and supernatants were collected. We solubilized the pellet
to assess intracellular insulin content. Insulin was measured by ELISA (Crystal
Chem).
Real-time measurements of mitochondrial oxygen consumption rate (OCR)
were performed using the XF24 extracellular flux analyzer instrument and the
AKOS algorithm (Seahorse). Islets were rinsed with sodium-bicarbonate-free
DMEM supplemented with 0.5% BSA and 3 mM glucose, and 60 islets were
distributed per well. After baseline measurements, substrates or inhibitors of
interests were injected. In each experiment, the injection order was as fol-
lows: glucose (20 mM), oligomycin (5 mM), and rotenone and antimycin A
(5 mM). The respiratory rate of each islet sample was measured at 37C
and analyzed.
For measurements of cytoplasmic free Ca2+ concentration, islets were
loaded with 2 mM Fura-2/AM (Molecular Probes) for 60 min in the presence
or absence of 100 nM C3a in a buffer containing (in mM) 125 NaCl, 5.9 KCl,
1.28 CaCl2, 1.2 MgCl2, 25 HEPES, and 3 glucose and 0.1%BSA (pH 7.4). After
loading, a single islet was transferred to an open perifusion chamber main-
tained at 37C, and [Ca2+]i was measured as the 340/380 nm fluorescence
ratio using a Spex Fluorolog spectrophotometer coupled to a Zeiss Axiovert
35 M microscope with a Zeiss Fluar 40 3 /1.30 oil objective (Carl Zeiss). Con-
centrations of 20 mM glucose and 50 mM KCl (in the presence of 3 mM
glucose) were used for islet stimulation.
For measurements of intracellular ATP, batches of 50 islets were incubated
in Krebs buffer with 3 mM glucose for 1 hr and then transferred to Krebs buffer
containing 3 or 20 mM glucose with C3a. ATP levels were quantified by the
CellTiter-Glo kit (Promega) with ATP standards.
For flow cytometry, islets were dispersed into a single-cell suspension with
trypsin/EDTA treatment. After standard staining with primary and secondary
antibodies, the cells were analyzed on a FACSCanto II (BD Biosciences).
Light Microscopy and Histological Analyses
For histological studies of islets, pancreata were dissected, fixed in 10%
formalin, and laid flat for paraffin embedding. Paraffin sections with the largest
tissue surface area were used. For insulin immunohistochemistry, we used an
anti-insulin antibody (Dako) with biotinylated anti-guinea pig antibody. HRP-
conjugated Avidin-biotin complex reagent was used following the manufac-
turer’s protocol (Vector). Signals were developed using DAB. For islet counting
and b cell area determination, images covering the entire section were
obtained. Islet and total pancreas cross-sectional areas were analyzed with
Aperio Imagescope. For insulin and Mac-2 immunofluorescence staining,
slides were blocked and then incubated with anti-insulin (Dako) and anti-
Mac-2 (Cedarlane) antibodies. Slides were washed in PBS and incubated
with fluorescently labeled anti-guinea pig and anti-rat antibodies (Life Technol-
ogies). 40–60 islets from each pancreas were scored for islet-associated
macrophages. Fluorescence images were captured on a Nikon Ti inverted
microscope equipped with a cooled charge-coupled device (CCD) camera
(Orca R2, Hamamatsu), 203 PlanApo VC NA0.75 objective, and Lumencor
Sola LED light source using NIS-Elements software.
For immunohistochemistry analysis of crown-like structures (CLS), serial
sections were incubated with anti-MAC-2 (Cedarlane) primary antibody. Bio-
tinylated and HRP-conjugated secondary antibodies were from Vector. Histo-
chemical reactions were performed using Vectastain ABC Kit (Vector) and
Sigma Fast 3,30-diaminobenzidine (Sigma) as the substrate. Sections were
counterstained with hematoxylin. Toluidine blue staining was used to
enumerate mast cells in purple (metachromatic staining) with a blue back-
ground (orthochromatic staining) (Enerba¨ck et al., 1986). CLS and mast cell
density were obtained by counting the total number of CLS or mast cells in
each section compared with the total number of adipocytes and expressed
as number/10,000 adipocytes.
Patient Studies
We investigated Adipsin, Leptin, and Adiponectin mRNA expression in paired
omental and subcutaneous adipose tissue samples obtained from 187
extensively characterized Caucasian obese men (n = 65) and women (n =
130) who underwent open abdominal surgery for elective cholecystectomy,
sleeve gastrectomy, and Roux-en-Y bypass surgery as described previously
(Blu¨her et al., 2009). With oral glucose tolerance tests, we identified
individuals with T2DM (n = 90) or normal glucose tolerance (NGT) (n = 97).
Among the T2DM cohort, 42 obese individuals (BMI = 34.3 ± 4.9 kg/m2)
were matched for age, gender, BMI, and body fat mass, and then patients
were grouped according to treatments with insulin alone or metformin (2g
BID). The phenotypic characteristics of the two study groups are given in
Table S1. All study protocols have been approved by the ethics committee
of the University of Leipzig. All participants gave written informed consent
before taking part in the study.
Plasma insulin was measured with an enzyme immunometric assay for the
IMMULITE automated analyzer (Diagnostic Products). Adiponectin and leptin
serum concentrations were measured as previously described (Klo¨ting et al.,
2010). Serum adipsin was measured by an ELISA (Aviscera). Human Adipsin,
Leptin, and Adiponectin mRNA expression were measured by quantitative
TaqMan assay, and fluorescence was detected on an ABI PRISM 7000
sequence detector (Applied Biosystems). Adiponectin and Leptin expression
were measured as described previously (Klo¨ting et al., 2010). Human Adipsin,
Leptin, and Adiponectin mRNA expression were calculated relative to the
mRNA expression of Hypoxanthine phosphoribosyltransferase 1 (HPRT1), all
determined by premixed assays on demand (Applied Biosystems). The
following statistical tests were used: paired Student’s test, chi quadrate test,
and Pearson’s simple correlation. Statistical analysis was performed using
SPSS version 12.0.
Statistical Analyses
Unless otherwise stated, data are presented as mean ± SEM. Statistical
analysis was carried out using Student’s t test when comparing two groups
and ANOVA when comparing multiple groups. Differences were considered
significant at p < 0.05.
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